What are the symptoms and treatment of Cytomegalovirus (CMV) colitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Symptoms of CMV Colitis

CMV colitis presents with nonspecific gastrointestinal symptoms including diarrhea, rectal bleeding, fever, abdominal pain, and weight loss, with life-threatening complications including massive hemorrhage and colonic perforation. 1

Clinical Presentation

Common Symptoms

  • Diarrhea (often debilitating and persistent) 1
  • Rectal bleeding (ranging from occult blood to massive hemorrhage) 1
  • Fever (frequently present) 1
  • Abdominal pain (variable location and severity) 1
  • Weight loss and anorexia (indicating chronic disease burden) 1
  • Malaise (generalized weakness and fatigue) 1

Absence of Classic CMV Viremia Symptoms

Patients with CMV colitis typically do NOT present with the classic CMV viremia triad of pharyngitis, lymphadenopathy, and splenomegaly. 1, 2 This is a critical diagnostic pitfall—the absence of these systemic symptoms should not exclude CMV colitis from your differential diagnosis.

Life-Threatening Complications

Surgical Emergencies

  • Toxic megacolon (requires emergency colectomy) 1, 3
  • Colonic perforation (surgical emergency with high mortality) 1
  • Fulminant colitis (rapidly progressive bowel wall necrosis) 1, 3
  • Extensive mucosal hemorrhage (can be life-threatening) 1
  • Bowel ischemia (from CMV-induced vasculitis) 1

High-Risk Populations

Immunocompromised Patients

CMV colitis occurs predominantly in severely immunosuppressed individuals:

  • HIV/AIDS patients with CD4+ counts <50 cells/µL 1
  • Solid organ transplant recipients (4.9% 10-year cumulative incidence post-liver transplant) 1, 2
  • Hematopoietic stem cell transplant recipients (15-25% incidence of CMV end-organ disease) 1, 2
  • Patients on immunosuppressive therapy (corticosteroids, azathioprine, methotrexate—OR 1.95) 2
  • Anti-TNF therapy recipients (OR 11.13 for CMV colitis) 2
  • Patients with malignancies (particularly acute lymphoblastic leukemia in pediatrics) 1

Inflammatory Bowel Disease Association

Patients with IBD who develop CMV colitis experience up to seven times higher in-hospital mortality compared to CMV colitis alone. 1, 2 Steroid-refractory IBD is particularly associated with CMV reactivation. 2, 4

Endoscopic Findings

Characteristic Ulcer Appearance

  • Punched-out ulcerations with well-defined borders (present in up to 80% of cases) 1, 2
  • Cecal ulcers involving the ileocecal valve (specific finding in graft-versus-host disease patients) 1
  • Pancolic involvement is rare (helps differentiate from Clostridioides difficile colitis) 1

Mortality Risk

In-hospital mortality of immunocompromised patients with severe CMV colitis approaches or exceeds 70% even with treatment. 1, 5 This extraordinarily high mortality rate underscores the critical importance of early recognition and aggressive management.

Diagnostic Pitfalls to Avoid

Blood Serology Has No Value

CMV blood serology is diagnostically useless for CMV colitis, as at least 70% of adults are CMV seropositive. 1, 2 Do not order or rely on CMV IgG/IgM antibodies for diagnosis.

Diagnosis Requires Tissue Confirmation

  • CMV-specific immunohistochemistry on colonic biopsies is the gold standard (sensitivity 78-93%, specificity 92-100%) 1, 3
  • "Owl eye" inclusion bodies on hematoxylin-eosin staining are highly specific but less sensitive 1
  • Colonic tissue CMV DNA PCR improves sensitivity (use viral load cut-off >250 copies/mg tissue for clinical significance) 3

Imaging Findings

Contrast-enhanced CT demonstrates bowel wall thickening (almost always present) with small bowel involvement in up to 40% of cases. 1 Pancolic thickening is rare and helps distinguish CMV colitis from C. difficile colitis.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cytomegalovirus Colitis Evaluation and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

CMV Colitis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of CMV Colitis in Severe Combined Immunodeficiency (SCID)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.